Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0. After: Measure: Part 1: Incidence of adverse events (AEs) and serious adverse events (SAEs) Measure: Part 2: Progression-free survival (PFS) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0 Measure: Part 3 Objective Response Rate (ORR) (Complete Response (CR), Partial Response (PR) and Minor Response (MR)) assessed by Blinded Independent Central Review (BICR) per Response Assessment in Neuro-Oncology (RANO) 2.0.
Planned enrollment increased by 240 participants
Before: 125 participants (planned). After: 365 participants (planned).
Primary completion date changed
Before: 1 Dec 2027. After: 1 Dec 2028.
Phase changed
Before: PHASE2. After: PHASE3.